Dermatology

4/30/25 → 4/29/35

Project: Research project

A PHASE 3, EXTERNAL AND SYNTHETIC PLACEBO-CONTROLLED RANDOMIZED STUDY WITH DOSE-UP FOR NON-RESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG...

3/17/25 → 3/16/35

Project: Research project

A PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF RO7790121 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Bigliardi, P. L. (PI)

GENENTECH, INC.

3/11/25 → 3/10/35

Project: Research project

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-DOSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VDPHL01 IN MALE SUBJECTS WITH ANDROGENETIC ALOPECIA

VERADERMICS INC

12/11/24 → 12/10/25

Project: Research project

PRESTO; Characterization and clinical outcomes of Alopecia Areata (AA) patients treated with ritlecitinib in a real-world (RW) cohort: A multinational, prospective observational study

6/10/24 → 6/9/35

Project: Research project

A Phase 2, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety andEfficacy of Enpatoran in Participants with Subacute Cutaneous Lupus Erythematosus, Discoid LupusErythematosus and/or Systemic Lupus Erythematosus Havin

MERCK AND CO INC

3/26/24 → 11/30/33

Project: Research project

Protocol M23-716: A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacyand safety of upadacitinib in adult and adolescent subjects with severe alopecia areata Protocol Date:01June 2023

THE GENEVA FOUNDATION, UNIFORMED SVC UNIV OF THE HEALTH SCI

ABBVIE INC

9/29/23 → 9/30/33

Project: Research project

Human Organ-on-Chip Platforms for Assessment and Development of Countermeasures for Radiation Exposure

Panoskaltsis-Mortari, A. (PI), Azarin, S. M. (CoI), Bigliardi Qi, M. (CoI) & Ogle, B. M. (CoI)

9/25/23 → 9/24/27

Project: Research project

A Phase 1b\2,Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients with Systemic Lupus Erythematous and Active Cutaneous Lupus Erythematosus

DAIICHI SANKYO, INC.

5/25/23 → 5/31/26

Project: Research project

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Baricitinib in Children from 6 Years to Less than 18 Years of Age with Alopecia Areata

ELI LILLY AND COMPANY

5/22/23 → 5/31/33

Project: Research project

A 6-month phase 3, multicenter, prospective, randomized, double-blind, vehicle-controlled study, to evaluate the efficacy and safety of topically applied clascoterone (cortexolone 17a-propionate) solution for the treatment of androgenetic alopecia in mal

CASSIOPEA, S.P.A.

4/10/23 → 4/30/28

Project: Research project

A Parallel Group Treatment, Phase 2a, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Farudodstat Tablets Compared with its Placebo in Male or Female Alopecia Areata Participants Aged 18 Years and Older with 50% or Greater Scalp Hai

ASLAN PHARMACEUTICALS (USA) INC

3/10/23 → 3/31/28

Project: Research project

A Phase 1/2a, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) And Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy

Schultz, B. J. (PI) & Bigliardi, P. L. (Prior Principal Investigator)

UCB PHARMA S.A.

2/23/23 → 2/28/28

Project: Research project

A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP, MULTI-DOSE STUDY TOEVALUATE THE EFFICACY AND SAFETY OF TDM-105795 IN MALE SUBJECTS WITH ANDROGENETICALOPECIA

TECHNODERMA MEDICINES INC.

12/29/22 → 12/31/27

Project: Research project

A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata

ARCUTIS BIOTHERAPEUTICS, INC

12/6/22 → 6/30/25

Project: Research project

Development and Validation of an Ancillary Diagnostic Test for Mycosis Fungoides (SIGNAL-MF)

Bohjanen, K. A. (PI)

CASTLE BIOSCIENCES, INC.

10/18/22 → 10/31/27

Project: Research project

A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate theEfficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants receiving Standard of Care

EMD SERONO RESEARCH & DEVELOPMENT INST

10/7/22 → 10/31/27

Project: Research project

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus (Subacute Cutaneous Lupus Erythematos

EMD SERONO RESEARCH & DEVELOPMENT INST

8/1/22 → 8/31/26

Project: Research project

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Useof Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD)

Schultz, B. J. (PI)

ASTRAZENECA

5/23/22 → 5/31/27

Project: Research project

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety ofRosnilimab (ANB030) in the Treatment of Subjects with Alopecia Areata

ANAPTYSBIO, INC

12/9/21 → 12/31/26

Project: Research project

A MULTICENTER, OPEN-LABEL, EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY ANDEFFICACY OF CTP-543 IN ADULT PATIENTS WITHMODERATE TO SEVERE ALOPECIA AREATA

CONCERT PHARMACEUTICALS, INC.

5/20/21 → 5/31/26

Project: Research project

A STUDY TO EVALUATE MAINTENANCE OF HAIR REGROWTH FOLLOWINGDOSE REDUCTION OF CTP-543 IN ADULT PATIENTS WITH MODERATE TOSEVERE ALOPECIA AREATA

CONCERT PHARMACEUTICALS, INC.

3/1/21 → 3/30/26

Project: Research project

Measuring Alopecia Areata Patient-Reported Psychosocial Outcomes: Scale Development and Validation

10/7/20 → 12/31/25

Project: Research project

An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904to Evaluate the Safety, Tolerability, and Efficacy of EfgartigimodPH20 SC in Patients With Pemphigus

Bohjanen, K. A. (PI)

ARGENX

9/17/20 → 9/30/25

Project: Research project

A Randomized, Double-Blinded, Double-Dummy, Active-Comparator Trial to Investigate the Efficacy,Safety, and Tolerability of Efgartigimod PH20 SC Compared to Rituximab in Adult Patients with Moderateor Severe Pemphigus (Vulgaris or Foliaceus)

Bohjanen, K. A. (PI)

ARGENX

8/19/20 → 8/30/25

Project: Research project

A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects with Gorlin Syndrome (Basal Cell Nevus Syndrome)

Maher, I. (PI)

PELLEPHARM, INC.

5/18/20 → 5/31/25

Project: Research project

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, with a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects with Moderate-to-Severe AlopeciaAreata

ARENA PHARMACEUTICALS, INC.

5/14/20 → 5/31/25

Project: Research project

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CTP-543 IN ADULT PATIENTS WITH MODERATE TO SEVERE ALOPECIA AREATA

CONCERT PHARMACEUTICALS, INC.

5/1/20 → 7/30/25

Project: Research project

A Multicenter, Randomized, Double-Blind, PlaceboControlled, Operationally Seamless, Adaptive Phase 2/3Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very SevereAlopecia Areata